New smart drug takes aim at Hard-to-Treat brain cancers
NCT ID NCT07268053
First seen Jan 05, 2026 · Last updated Jun 23, 2026 · Updated 31 times
Summary
This early-phase trial is testing an investigational drug called risvutatug rezetecan in 15 people with recurrent glioblastoma or brain metastases. The drug is designed to seek out and deliver a cancer-killing payload to tumor cells. The study first measures how much drug gets into the tumor during surgery, then offers additional doses to those who show a good response, while closely monitoring safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA (GBM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
St. Joseph's Hospital and Medical Center
RECRUITINGPhoenix, Arizona, 85013, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
risvutatug rezetecan (a targeted antibody-drug conjugate)
What this could lead to
If it works, this could point toward a new treatment option for aggressive brain tumors that have come back after standard therapy.
What could go wrong
This is a very early, small study (15 people) focused on safety and drug levels, not yet testing if it truly helps patients. The drug may not reach all tumor cells or could cause side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.